Approval · Notice of Compliance 1554 · 2003
MEVACOR: Notice of Compliance 1554
Issued October 24, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1554
- Date
- October 24, 2003
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised product monograph: changes to dosage & administration and warnings sections with regards to rhabdomyolysis
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MEVACOR | Not yet assigned | — |
Medicinal ingredients
- LOVASTATIN 10 MG per TAB
- LOVASTATIN 20 MG per TAB
- LOVASTATIN 40 MG per TAB